Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Idiopathic noncirrhotic portal hypertension Indication Strategy Report 2026: Endothelin, Trials and Deals
3 August 2026
2026 Idiopathic noncirrhotic portal hypertension indication strategy covering epidemiology, Endothelin biology, active trials, transactions, unmet need,…
Latest Hotspot
8 min read
Sinusoidal obstruction syndrome Indication Strategy Report 2026: PAI-1, Trials and Deals
3 August 2026
2026 Sinusoidal obstruction syndrome indication strategy covering epidemiology, PAI-1 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Budd-Chiari syndrome Indication Strategy Report 2026: JAK2, Trials and Deals
3 August 2026
2026 Budd-Chiari syndrome indication strategy covering epidemiology, JAK2 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Portal vein thrombosis Indication Strategy Report 2026: FXI, Trials and Deals
3 August 2026
2026 Portal vein thrombosis indication strategy covering epidemiology, FXI biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Congenital hepatic fibrosis Indication Strategy Report 2026: PKHD1, Trials and Deals
3 August 2026
2026 Congenital hepatic fibrosis indication strategy covering epidemiology, PKHD1 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Alpha-1 antitrypsin deficiency liver disease Indication Strategy Report 2026: SERPINA1, Trials and Deals
3 August 2026
2026 Alpha-1 antitrypsin deficiency liver disease indication strategy covering epidemiology, SERPINA1 biology, active trials, transactions, unmet need,…
Latest Hotspot
8 min read
Crigler-Najjar syndrome type 1 Indication Strategy Report 2026: UGT1A1, Trials and Deals
3 August 2026
2026 Crigler-Najjar syndrome type 1 indication strategy covering epidemiology, UGT1A1 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Wilson disease with hepatic presentation Indication Strategy Report 2026: ATP7B, Trials and Deals
3 August 2026
2026 Wilson disease with hepatic presentation indication strategy covering epidemiology, ATP7B biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Gilbert syndrome Indication Strategy Report 2026: UGT1A1, Trials and Deals
3 August 2026
2026 Gilbert syndrome indication strategy covering epidemiology, UGT1A1 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Rotor syndrome Indication Strategy Report 2026: SLCO1B1, Trials and Deals
3 August 2026
2026 Rotor syndrome indication strategy covering epidemiology, SLCO1B1 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Dubin-Johnson syndrome Indication Strategy Report 2026: ABCC2, Trials and Deals
3 August 2026
2026 Dubin-Johnson syndrome indication strategy covering epidemiology, ABCC2 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Benign recurrent intrahepatic cholestasis Indication Strategy Report 2026: ATP8B1, Trials and Deals
3 August 2026
2026 Benign recurrent intrahepatic cholestasis indication strategy covering epidemiology, ATP8B1 biology, active trials, transactions, unmet need, competition…